Outlook Therapeutics Inc. (NASDAQ:OTLK) currently has a daily average trading volume of 3.21M but it saw 8153406 shares traded on Wednesday. With a market cap of 180.33M USDstock’s current market price of $1.53 came rising about 9.29 while comparing to the previous closing price of $1.40. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.06 and as low as $0.50. In the recent trading on the day, stock has struck highest price mark of $1.59 while lowest mark touched by it was $1.36.
Taking a look at 20-day trading activity of Outlook Therapeutics Inc. (OTLK) gives us an average price of $1.3850, while its current price level is -25.72% below from 52-week high level whereas it is 206.61% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.3534 while that of 200 days or SMA-200 reads an average of $0.9987. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.84% during that period while stretching the period over a month that decreases to 8.14%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 61.13 which implies that the stock is in neutral territory.
Outlook Therapeutics Inc. (OTLK)’s stock is currently under the radar of 5 analysts who are in consensus at a 12-month price target range of between $3.25 and $8.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $3.25 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $8.00. Average price target assigned by them is $5.65 which highlights an upside potential of 72.92% for the stock over that period. And to attain the median price target of $6.00 assigned by those analysts, stock has to add about 74.5% of value to its current levels.
Data by FactSet Research shows that 5 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 5 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Strong Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Ladenburg Thalmann which initiated the stock as “Buy” in its note to investors issued on September 11, 2019, recommending a price target of $9 for it. Ascendiant Capital Markets also issued its recommendations for the stock as it initiated the price target for the stock is.
Over the week, OTLK’s stock price is moving 12.50% up while it is -2.55% when we observe its performance for the past one month. Year-to-date it is 159.32% up and over the past year, the stock is showing a downside performance of -19.47%.
The latest quarterly earnings report issued by the company was for quarter ended 6/29/2020, when its quarterly earnings per share (EPS) of -$0.11 beat the consensus estimate of -$0.11 for the same. The company is expected to be releasing its next quarterly report in 12/16/2020, for which analysts forecasted an EPS of -$0.12 while estimate for next year EPS is -$0.56. For OTLK, analysts are forecasting an EPS-growth rate of 54.80% for current year and estimate for EPS growth in next year is 10.70%. In next quarter, company is expected to be making quarterly sales of $320k as analysts are expecting the sales for current fiscal year at $260k and seeing the company making $510k in sales next year. Moreover, analysts are in estimates of $130k for current-quarter revenue.
Currently, Outlook Therapeutics Inc.’s total number of outstanding shares is 47.90M. Company’s return on investment (ROI) stands at 2576.60% and return on equity (ROE) at 240.80%. Stock’s beta reads 0.36. Stock has a price to sale or P/S ratio amounts to 28.18. Its return on asset (ROA) is -241.40% on average.
A filing at the U.S. Securities and Exchange Commission revealed that Vanguard Extended Market Index Fu came shrinking its share ownership by 0.00% in the Outlook Therapeutics Inc. (OTLK) decreasing its stake to 0.25% with control over 0.0 shares in the company. As per SEC documents, Vanguard Extended Market Index Fu shunned 307,542 of company’s common stock of worth $0.42 million as per recent closing price of the stock. Vanguard Extended Market Index Fu is not the only institutional holder which restructured its stake in Outlook Therapeutics Inc., as Vanguard Total Stock Market Index dumped 223,704 shares of worth $0.3 million to bring its holdings to a total of 0.0 shares. In the most recent quarter, Fidelity Nasdaq Composite Index F came cutting its stake by 0.00% in the company and now holds 49059.0 or 0.04% of the company’s stake having worth of about 66720.0.